Anticoagulant drugs antagonize coagulation and are used to prevent or cure (recurrent)
venous thromboembolism (VTE). Drugs to prevent clotting have been used for more than a …

There are four potential outcomes when a patient commences a new drug and its effects are
assessed at the correct time. First, the new drug provides no clinical benefits and gives the …

Introduction: This is a review of the drug interactions (DIs) between newer antidepressants
and oral anticoagulants (OACs): vitamin K antagonists (VKAs) and direct-acting OACs …

Purpose Non-vitamin K antagonist oral anticoagulants (NOACs) are widely used in patients
with atrial fibrillation (AF) because of their effectiveness in preventing stroke and their better …

Venous thromboembolism (VTE), which includes pulmonary embolism and deep vein
thrombosis, is a condition characterized by abnormal blood clot formation in the pulmonary …

Introduction Direct oral anticoagulants (DOAC) are the guideline-recommended therapy for
prevention of stroke in atrial fibrillation (AF) and venous thromboembolism. Since …

Background Routinely used cardiac medications, based on pharmacokinetics, are
hypothesized to increase drug levels of direct oral anticoagulants (DOACs), with the …

Abstract Background Direct oral anticoagulants (DOACs) have been used for both primary
and secondary prevention of cerebral infarction in older patients with atrial fibrillation (AF) …

Personalized medicine has been a booming area in clinical research for the past decade, in
which the detailed information about the patient genotype and clinical conditions were …

Background: Co-prescribing medications that can interact with direct-acting oral
anticoagulants (DOACs) may decrease their safety and efficacy. The aim of this study was to …